Dow Venture Capital, the corporate venturing unit of US-based Dow Chemical Company, has reinvested in Germany-based healthcare company Noxxon Pharma’s fourth round of funding.

Noxxon raised €33m ($40.8m) in its series D round led by US and Germany-based venture capital firm NGN Capital as a new investor. NGN’s VC and German state-backed peers, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin, FCP Op Medical BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?